drugset / Trial / NCT06478225
Evaluate the Safety and Efficacy of BGT007H Cell Therapy in Patients With Relapsed/Refractory Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the safety and tolerability of BGT007H cell therapy in patients with recurrent/refractory pancreatic cancer.
Timeline
- Start
- 2024-05-07
- Primary completion
- 2027-03-31
- Completion
- 2027-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BGT007H | Cell therapy | 3e+07 cells | Other |
| Subject | BGT007H | Cell therapy | 1e+08 cells | Other |
| Subject | BGT007H | Cell therapy | 2e+08 cells | Other |
| Subject | BGT007H | Cell therapy | 3e+08 cells | Other |
| Subject | BGT007H | Cell therapy | 4e+08 cells | Other |